Viking Therapeutics, Inc.

LSE:0VQA Stock Report

Market Cap: US$3.3b

Viking Therapeutics Management

Management criteria checks 2/4

Viking Therapeutics' CEO is Brian Lian, appointed in Sep 2012, has a tenure of 12.42 years. total yearly compensation is $12.63M, comprised of 4.9% salary and 95.1% bonuses, including company stock and options. directly owns 1.77% of the company’s shares, worth $57.62M. The average tenure of the management team and the board of directors is 5.5 years and 10.8 years respectively.

Key information

Brian Lian

Chief executive officer

US$12.6m

Total compensation

CEO salary percentage4.9%
CEO tenure12.4yrs
CEO ownership1.8%
Management average tenure5.5yrs
Board average tenure10.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brian Lian's remuneration changed compared to Viking Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-US$110m

Sep 30 2024n/an/a

-US$99m

Jun 30 2024n/an/a

-US$97m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$13mUS$615k

-US$86m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$5mUS$612k

-US$69m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$59m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$4mUS$594k

-US$55m

Sep 30 2021n/an/a

-US$54m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$5mUS$577k

-US$39m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$4mUS$525k

-US$26m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$1mUS$485k

-US$22m

Compensation vs Market: Brian's total compensation ($USD12.63M) is above average for companies of similar size in the UK market ($USD2.95M).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.

CEO

Brian Lian (58 yo)

12.4yrs

Tenure

US$12,628,061

Compensation

Dr. Brian Lian, Ph D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian has been an Inde...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Lian
President12.4yrsUS$12.63m1.77%
$ 57.6m
Gregory Zante
Chief Financial Officer5.5yrsUS$3.50m0.026%
$ 859.9k
Marianne Mancini
Chief Operating Officer4.1yrsUS$3.51m0.21%
$ 7.0m
Michael Morneau
Vice President of Finance & Administration6.8yrsUS$619.56kno data
Geoffrey Barker
Chief Development Officer2.1yrsno datano data

5.5yrs

Average Tenure

58.5yo

Average Age

Experienced Management: 0VQA's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Lian
President12.4yrsUS$12.63m1.77%
$ 57.6m
Scott Hecker
Scientific Advisorno datano datano data
Matthew Foehr
Independent Director10.8yrsUS$169.37k0.10%
$ 3.3m
J. Singleton
Independent Director10.8yrsUS$192.77k0.0085%
$ 277.8k
Charles Rowland
Independent Director7.6yrsUS$189.62k0.027%
$ 877.9k
Alan Cherrington
Scientific Advisorno datano datano data
G. Alexander Fleming
Scientific Advisorno datano datano data
Jay Magaziner
Scientific Advisorno datano datano data
David Bullough
Scientific Advisorno datano datano data
Lawson MacArtney
Independent Chairman10.8yrsUS$222.72k0.043%
$ 1.4m
Stephan Kemp
Scientific Advisorno datano datano data
S. Rouan
Independent Director5.6yrsUS$178.65k0%
$ 0

10.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 0VQA's board of directors are seasoned and experienced ( 10.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 06:27
End of Day Share Price 2025/02/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viking Therapeutics, Inc. is covered by 28 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Justin ZelinBTIG